[A20-16] Niraparib (ovarian cancer) - Addendum to Commission A19-88
Last updated 02.04.2020
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).
Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy
The data subsequently submitted have changed the conclusion of the assessment: now hint of lesser benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.